Strategic merger Opportunity to engage early with Fulcrum around post-merger integration and potential co-development or licensing discussions with Slate Medicines, leveraging combined capabilities in rare disease programs.

Rare disease focus Target outreach emphasizing solutions for genetically defined rare diseases, aligning with Fulcrum's clinical-stage portfolio and potential need for specialized CROs, biomarkers, and patient recruitment partnerships.

Sickle cell collaboration Peak interest in expanding partnerships related to pociredir and calmodulin pathway programs; propose diagnostic, care pathways, or emergency department workflow integrations leveraging MedicAlert and SCDAA collaborations.

Funding and growth Position offerings around scalable manufacturing, data analytics, and real-world evidence generation to support ongoing clinical trials in a company with substantial funding and revenue in the low to mid single digits.

Regulatory and risk monitoring Acknowledge ongoing securities investigations and stock volatility; present solutions that help with regulatory intelligence, compliance services, and investor communications support to reduce risk and facilitate transparent collaborations.